SOLICITATION NOTICE
Q -- LABORATORY TESTING SERVICES
- Notice Date
- 12/13/2006
- Notice Type
- Solicitation Notice
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, Nat'l Institute of Diabetes, Digestive, & Kidney Diseases, 2 Democracy Plaza, Suite 700W 6707 Democracy Blvd., MSC 5455, Bethesda, MD, 20892-5455, UNITED STATES
- ZIP Code
- 00000
- Solicitation Number
- NIH-NIDDK-07-064
- Response Due
- 12/27/2006
- Archive Date
- 1/11/2007
- Description
- This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation and a separate written solicitation will not be issued. This solicitation number is NIH-NIDDK-07-64 and is issued as a Request for Quotation (RFQ). The solicitation/contract will include all applicable provisions and clauses in effect through Federal Acquisition Circular 2001-27. The North American Industry Classification (NAICS) Code is 334516 and the business size standard is 500 employees. This acquisition is being conducted using Simplified Acquisition Procedures in accordance with FAR Part 13. However, this solicitation is not set aside for small business. It is the intent of the National Institutes of Health (NIH); National Institute of Child Health and Human Development (NICHD) to procure from Mayo Collaborative Services Inc, 200 SW 1ST Street, Rochester, MN 55905 perform assays for measuring the following materials: GHBP Growth Horm Bind Prot, Cortisol Binding Globulin, Plasma Renin Activity, CBG with Free Cortisol, Cortisol, Free, Cortisol, Saliva, Cortisol, Urine, DHEA-Serum, Testosterone, Total & Free, Testosterone, Free, Testosterone, Total only, Andostenedine, Serum, IGF Binding Prot, 1, IGFBP-3, S, Sex Hormone Binding Glob, Leptin, Estrone, Serum, Vitamin D, 1,25-Dihydroxy, Renin, Renin Esoterix, Renin Plasma, Renin Activity, Plasma, 21 Hydroxylase Ab, S, Bone Alkaline Phosphatase, 17 Hydroxyprogesterone, Estradiol, Enhanced, S, 17 Hydroxy-Pregnenolone, Aldosterone, Serum, Estrone, Serum, Quant, each specimen, Creatinine, Urine, Adrenal AB, 11 Desoxycortisol, Dexamenthasone, Histamine Blood, Pyridinoln+Deoxypyrid, Ur and Bone Alkaline Phospatase. The NIH Clinical Center Department of Laboratory Medicine (DLM) will receive, accession, and process NICHD patient blood specimens for clinical laboratory testing, using the DLM central accessioning group and the on-site Mayo Medical Laboratories (MML) staff to process these samples. Specimens shall be picked up from the Department of Laboratory Medicine on the 2nd floor of the Clinical Center of the NIH daily. Specimens shall be maintained immediately at dry ice temperatures and maintained in the frozen state until assayed. All specimens will be furnished by the Government. Patient Assays shall be performed and the results reported to the NIH within seven (7) calendar days after pick-up when authorized by performing physician. Emergency samples shall be performed and the results reported with three (3) calendar days. All samples shall be assayed in duplicate in manual pipetted assays (automated instrumental assays showing low variability may not be run in duplicate) to allow the calculations of within-assay variance for each assay. A coefficient of variations shall be calculated for each assay and between assay variation shall be determined as a running mean. A quality control system shall be established with a minimum of two (2) quality control sample pools in each assay. All samples shall be kept in cold storage (.:::: -70 degrees C) for up to approximately ninety days, and then will be made available for transfer as governed under NICHD/McKesson Bioservices Freezer Repository Contract. The laboratory must be certified by the Nuclear Regulatory Commission or the governing regulatory authority. The Contractor shall be available for discussion of assay results and problems and shall be the capability to modify or extend existing assays and develop related methods for additional hormones or drugs using the below-mentioned standard approaches as required by the Project Officer (requestor). One of the missions of the NICHD Clinical Director is to provide treatment and laboratory testing to patients who are enrolled in ongoing clinical protocols. Researchers are required to process samples for protocol studies through the Office of the Clinical Director. Mayo Medical Laboratories (MML), in collaboration with the NIH Clinical Center Department of Laboratory Medicine, has been providing this service to NICHD since 2002, through contracts with the Clinical Center and with NICHD. MML is familiar with the standards, practices, quality control procedures and the implementation of the testing. Isolation, purification and the analysis of the assays are an integral part of clinical protocols to maintain consistency. MML is knowledgeable about the Government Privacy Regulations related to patient testing. They have the ability to analyze human samples and report these results to the NIH Clinical Center, Department of Laboratory Medicine. The offeror must include a completed copy of the following provisions: 1) FAR Clause 52.212-1 Instructions to Offerors ? Commercial; 2) FAR Clause 52.212-2, Evaluation ? Commercial Items. As stated in FAR Clause 52.212-2 (a), ?The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the Government, price and other factors considered.? The following factors shall be used to evaluate offers: Technical Evaluation, Price, and Past Performance; 3) FAR Clause 52.212-3, Offeror Representations and Certifications ? Commercial Items; 4) FAR Clause 52.212-4, Contract Terms and Conditions Required To Implement Statues or Executive Orders ? Commercial Items, Contract Terms and Conditions ? Commercial Items; and 5) FAR Clause 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders ? Commercial Items ? Deviation for Simplified Acquisitions. This notice of intent is not a request for competitive quotations however; all responses received within 15 days from the date of publication of this synopsis will be considered by the Government. A determination by the Government not to compete this proposed acquisition is based upon responses to this notice and is solely for the purpose of determining whether to conduct a competitive acquisition. The offeror must include in their quotation, the unit price, the list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. The clauses are available in full text at http://www.arnet.gov/far. Interested vendors capable of furnishing the government with the item specified in this synopsis should submit their quotation to the below address. Quotations will be due fifteen (15) calendar days from the publication date of this synopsis or December 27, 2006. The quotation must reference ?Solicitation number? NIH-NIDDK-07-023. All responsible sources may submit a quotation, which if timely received, shall be considered by the agency. Quotations must be submitted in writing to the National Institute of Diabetes and Digestive and Kidney Diseases 6707 Democracy Blvd., Room 774B, Bethesda, Maryland 20817, Attention: V. Lynn Griffin. FAXED COPIES WILL NOT BE ACCEPTED.
- Record
- SN01195614-W 20061215/061213220327 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |